Vista Partners announced today that it has initiated coverage on Tapestry Pharmaceuticals (Nasdaq TTPH). Vista Partners provides independent, equity research for institutional and individual investors, with a focus on publicly traded small capitalization companies. Ross Silver and Jeremy Thum of Vista Partners issued the report.

Tapestry Pharmaceuticals, Inc., together with its subsidiaries, develops therapies for the treatment of cancer. Its development stages therapeutic candidate products include TPI 287 IV, a Phase I product for prostate, nonsmall cell lung, and breast cancers; and TPI 287 oral formulation, a preclinical development stage product for prostate, nonsmall cell lung, ovarian, breast, and colon cancers. Tapestry Pharmaceuticals was founded in 1991 and is based in Boulder, Colorado.